LAGOS, Nigeria — Nigeria’s drug regulator says it has uncovered one of the country’s largest recent counterfeit-medicine operations, seizing more than 10 million doses of fake and banned pharmaceuticals from concealed warehouse compounds in Lagos, in what officials described as a major public-health threat.
Briefing reporters, NAFDAC’s Director of Investigation and Enforcement, Martins Iluyomade, said the raid followed intelligence gathered during a February 3 enforcement-training meeting that flagged suspicious activity around the Trade Fair–Navy corridor. He said inspection teams found multiple structures disguised as residential buildings but used strictly for bulk storage and distribution.
According to the agency, the seized products included counterfeit injectable anti-malarials, antibiotics, sachet formulations, blister-packed medicines and banned drugs such as Analgin. Officials said the operation’s estimated street value exceeds ₦3 billion, with eight trailers loaded with assorted fake medicines and cosmetic products evacuated from the site.
Iluyomade said the sophistication of the packaging made visual detection difficult even for experienced handlers, alleging that criminal networks now clone legitimate products closely enough to infiltrate normal supply channels. He described the operation as part of an organized cross-border scheme involving both local and foreign collaborators.
NAFDAC warned that counterfeit emergency drugs are especially dangerous because treatment delays or therapeutic failure can be fatal in severe cases such as cerebral malaria. The regulator urged consumers, hospitals, pharmacies and patent medicine vendors to avoid unusually cheap offers and to verify product legitimacy through approved supply chains and official alerts.
The Lagos discovery comes amid wider enforcement pressure by NAFDAC in major market hubs, including earlier seizures in Trade Fair areas and open-drug market crackdowns elsewhere in Nigeria. The agency has repeatedly argued that punitive laws and prosecution capacity must be strengthened to deter repeat offenders in high-profit counterfeit networks.
For public-health analysts, the raid highlights a recurring systemic risk: counterfeiters increasingly target high-demand medicines where price sensitivity is high and traceability is weak. (This is an inference based on enforcement patterns and product types reported.) If follow-up prosecutions, supply-chain audits and market surveillance are sustained, the seizure could mark a turning point. If not, experts warn, criminal operators may simply fragment stock and return through smaller channels that are harder to detect
